# Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

> **NCT02341807** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spark Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Choroideremia
- CHM (Choroideremia) Gene Mutations

## Interventions

- **BIOLOGICAL:** AAV2-hCHM

## Key facts

- **NCT ID:** NCT02341807
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-15
- **Primary completion:** 2022-10-12
- **Final completion:** 2022-10-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02341807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02341807, "Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02341807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*